Webinar replay · October 23, 2026

From biotech to tech-bio.

DiaGen AI is a Vancouver tech-bio company with two validated AI discovery platforms, BLACKCOMB for small molecules and CYPRESS for peptides, and a signed revenue-share contract with Hadassah and Ariel University. Watch the highlights from the October 23 shareholder webinar: the team, the Hadassah lead-optimization project, the KRAS catalog held at UNC, the L.I.V.E. longevity wearable, and the $0.07 unit financing that bridges to a planned public listing.

Request a call Download Deck
This webinar has been compressed to 22 minutes to give you a faster, better preview — the full session, tightened to the substance.
2
Validated AI platforms, both in partner deployment
7
Active partnerships across four regions
500M
Molecules in BLACKCOMB's foundation model
165
Shareholders, CAD $3.5M raised to date
$0.07
Unit price of the current bridge round
22-minute condensed cutRecorded October 23, 2026Corporate update webinar
What's inside the 22 minutes

Jump straight to the part you care about.

Every chapter below is a link into the recording. Click one and the player picks up there.

Platform demo

See BLACKCOMB at work.

A two-minute walkthrough of BLACKCOMB, DiaGen's small-molecule platform: its key features, capabilities and use cases. For how BLACKCOMB and CYPRESS, the peptide platform, work together, jump to the platforms chapter of the webinar.

Blackcomb Diagen Platform2-minute demoWatch on YouTube
Key slides

The deck, slide by slide.

Eight slides from the Q3 2026 deck. Click a slide to open it full size, or download the full 22-page deck.

Two validated AI protocols
Two validated AI protocolsBLACKCOMB for small molecules, CYPRESS for peptides; both in active partner deployment.
Seven partnerships and their status
Seven partnerships and their statusHadassah, UNC and Mila signed; a university lab under NDA; AKT Health, MetaNova and Contango as JVs.
Hadassah, Hadasit and Ariel University
Hadassah, Hadasit and Ariel UniversityBinding agreement on three projects; DiaGen shares milestones and royalties with a right of first refusal.
UNC Structural Genomics Consortium
UNC Structural Genomics ConsortiumDGEN1-5 KRAS catalog, pre-clinical, available for partnering, IP retained in full by DiaGen.
L.I.V.E. longevity wearable
L.I.V.E. longevity wearableA sweat-based biological age index built on five weighted aging pillars and 16+ screened proteins.
Cap structure and current financing
Cap structure and current financingCAD $3.5M raised, 90M shares out, 165 shareholders; a $1M bridge-to-exit unit offering at $0.07.
Exit-ready pathway
Exit-ready pathwaySale to an existing Nasdaq company under NDA, with reverse merger and IPO as alternative routes.
Why invest in DiaGen
Why invest in DiaGenThird-party validation, non-dilutive development, global reach, a decentralized data moat and a defined revenue path.
The deal

A $1M bridge-to-exit round at $0.07.

Terms as summarised on the capital structure slide of the Q3 2026 deck. On the webinar, management said about US$350K to US$400K remained open, with closing planned in tranches before US Thanksgiving. Full terms are in the subscription agreement.

Instrument
Units: one share + one-half warrant
Price per unit
$0.07
Warrant
$0.25 exercise, three years from closing
Size
Up to $1,000,000, subject to adjustment
Minimum
$25,000 (less for existing shareholders)
Jurisdictions
Canada, U.S. (Reg D 506(b)), others per law
Registered accounts
RRSP and TFSA eligible
Closing
In tranches, as determined by the company
Use of proceeds
  • Compute and delivery on the Hadassah and partner contractsHadassah
  • Three to four hires: ML engineer and a Silicon Valley biologistTeam
  • Expenses of a going-public transactionListing
  • General working capital on an 18-month, ~$1.5M budgetRunway
Non-brokered private placement to qualified investors under applicable exemptions; finder's fee of up to 8% cash and 8% broker warrants at $0.07. DiaGen AI Inc. is a private, non-reporting issuer formed in British Columbia and resale restrictions apply. Nothing on this page is an offer of securities; contact the company directly.
Partnerships

Seven partnerships, three signed.

From the portfolio slide of the Q3 2026 deck. Academic and institutional partners carry synthesis and wet-lab cost while DiaGen retains or shares the IP.

Hadassah — Hadasit / Ariel University
Three projects toward commercialization
Peptide and radiopharma co-development; revenue share
Signed
UNC — Structural Genomics Consortium
DGEN1-5 KRAS oncology catalog
Wet-lab validation, open science
Signed
Mila — Quebec AI Institute
Protein design support at scale
Government-supported research
Signed
University lab (to be announced)
CRP biosensor for longevity
Biosensor assets co-development
Under NDA
AKT Health
APAC and MENA pipeline sales
Advisory, clinical and global expansion
Advisory + JV
MetaNova Labs
Hit-picking tool, Bittensor SN68
Decentralized discovery and data
JV LOI
Contango / General Tensor
Decentralized discovery mining; $100K compute capex committed
DeSci compute and subnet support
JV announced
Who's running it

The team and their track record.

Eleven operators and advisors across Canada, the U.S., the UK, EU and UAE, per the Q3 2026 deck.

BD
Brian D. Keane
CEO and Chairman

26+ years in capital markets and $3B+ of transactions. Former advisor and banker at Rodman & Renshaw and Ladenburg Thalmann; early team at Yorkville Advisors. JD, New York Law School.

PL
Paolo Lobo
President and COO

MSc Biochemistry (UBC). 10+ years in IVD and biotech across business development, regulatory strategy and partnerships. Published in Nature.

AC
Andrew Chan
CFO

Finance and operations leader for early-stage startups. Former Finance Manager at Electronic Arts and Head of Finance at Xtract AI.

EB
Eric Baum
Co-Founder and Director

20+ years advising Fortune 50 companies. Co-founder of Solidea Capital, director at Acquis Consulting and SSI Strategy.

MP
Mohit Pandey
Chief AI Officer

PhD Bioinformatics (UBC), MS Computer Science (Rutgers). Formerly Recursion (Nasdaq: RXRX) and Weill Cornell; published at NeurIPS, ICML and in Nature.

SK
Dr. Sonny Kohli
Director and Chief Medical Advisor

ICU physician and McMaster faculty. Co-founded Cloud DX, winner of Canada's first Qualcomm Tricorder XPRIZE. Former CSA astronaut candidate. Leads L.I.V.E.

IS
Ivan Semenov
Computational Drug Design

MSc Bioorganic Chemistry (summa cum laude). 4+ years in pharma as a computational chemist, including Insilico Medicine. Leads CADD and AI-driven protein design.

NE
Noah El Rimawi-Fine
ML Engineer and Advisor

Master's at McGill and Mila researching ML for drug discovery, biomolecular design and genetics. Recently joined J&J.

AT
Aditya Tallapragada
Advisor

Founder of AKT Health. 15+ years in life sciences and clinical research applying AI to regulatory workflows. Built Impakt Health, a Japan-certified Class II SaMD.

MG
Mike Grantis
Advisor

7+ years investing in liquid tokens and private allocations. Co-founder and Managing Partner, Contango Digital Assets and General Tao Ventures.

PC
Paul Crath
Director and Legal Advisor

Partner and Head of Capital Markets at CMX Law, New York. 30+ years in capital markets, M&A and cross-border transactions.

Catalysts

What happens next.

  • Jun 2024
    Research collaboration with UNC's Structural Genomics Consortium
    KRAS degraders later confirmed active in cells
  • Nov 2024
    Partnership with Mila, Quebec AI Institute
    Protein design support at scale
  • 2025
    Scale AI Top 100 twice, VivaTech Paris delegation, NVIDIA Inception
    Eleven independent recognitions in three years
  • Nov 2025
    MetaNova Labs JV LOI and Frontiers in Aging paper
    Hit-picking tool on Bittensor SN68; the L.I.V.E. biomarker framework published
  • Jun 2026
    Hadassah and Ariel University revenue-share agreement signed
    Three projects toward commercialization after a 15-month negotiation
  • Oct 2026
    Shareholder webinar; bridge round open
    About US$100K closed at the time of the call
  • By late Nov 2026
    Bridge round closes in two tranches
    Before the US Thanksgiving period
  • Q4 2026
    New ML engineer and Silicon Valley biologist join
    Partner has GMP facilities and a diagnostics business
  • Next rounds
    Hadassah synthesises and tests the first optimized peptides
    Organoid results feed back into CYPRESS; FDA accepts organoid models in place of animal studies
  • Jan 2027
    JPMorgan Healthcare Conference week
    Management expects competing interest from public vehicles
  • 2027
    Going-public transaction
    Sale to an existing Nasdaq company is the active route; reverse merger and IPO are alternates
Capital snapshot

Where the cap table stands.

90M
Shares outstanding
165
Shareholders
CAD $3.5M
Capital raised to date
CAD $40K
Average investment
40% / 60%
Founder and insider / retail, institutional and family office
4.26%
Held by Frontier IP Group (LON: FIIP)

Per the capital structure and recognition slides of the Q3 2026 deck. Not pro forma for the units or warrants in the current round. Backers listed in the deck include Canaccord Genuity, Haywood Securities, Research Capital, Ventum Financial, Euroswiss, Carella, Solidea and Jemini Capital, JSTR Group and Maelstrom Family Office.

Documents

Do your diligence.

PDFTech-Bio Partnering deck, Q3 2026PRHadassah and Ariel University revenue-share agreement (Jun 2026)PRAditya Tallapragada joins advisory board (Mar 2026)PRMetaNova Labs joint venture LOI (Nov 2025)PRUNC Structural Genomics Consortium collaboration (Jun 2024)PAPERBiomarker integration and biosensor technologies enabling AI-driven insights into biological aging (Frontiers in Aging, 2025)WEBPlatform: BLACKCOMB and CYPRESSWEBPipelineWEBAll press releases
In the news

Latest on DiaGen AI

Company announcements and third-party coverage of DiaGen AI, refreshed from the company newsroom and Google News.

Updates automatically. Headlines link to the original publisher. View the full news feed →
Next step

Want the full picture?

Contact Brian Keane, chairman and CEO, to receive the data room, subscription agreement and platform walkthrough, or to book a call with management. The company is accepting existing shareholders below the stated minimum.

Request a call

Investor contact
Brian D. Keane
Chairman and CEO, DiaGen AI Inc. · Vancouver, British Columbia
Request more information